1. aFor selected examples of medicinal candidates with
N-methyl pyrazoles, see:Zak, M. E.; Rajapaksa, N. S.; Cheng, Y.X.; Grandner, J.; Shore, D. G. M.; Bryan, M. C.Pyrazolopyrimidine Inhibitors of JAK Kinases and Uses Thereof. US 11,453,671 B2, 2022.
2. bZak, M. E.; Rajapaksa, N. S.; Cheng, Y.X.; Grandner, J.; Shore, D. G. M.; Bryan, M. C. Pyrazolopyrimidine Sulfone Inhibitors of JAK Kinases and Uses Thereof. US 20,200,399,275 A1, 2020.
3. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling
4. dTamura, K.; Yamakawa, T.; Isshiki, S.; Wakiyama, Y.; Ouchi, S.; Matsuhira, T.; Ishida, N.; Tabata, Y. Novel Compound and Pharmacologically Acceptable Salt Thereof. US 201,932,268,6 A1, 2019.
5. eSaito, K.; Nakajima, K.; Taniguchi, T.; Iwamoto, O.; Shibuya, S.; Ogawa, Y.; Aoki, K.; Kurikawa, N.; Tanaka, S.; Ogitani, M.; Kioi, E.; Ito, K.; Nishihama, N.; Mikkaichi, T.; Saitoh, W. Griseofulvin compound. EP 343,810,3 A1, 2019.